drug_type
RELEVANT_DRUG
intervention_type
radiopharmaceutical (PSMA-targeted radioligand therapy)
drug_description
PSMA-targeted small-molecule radioligand linked to lutetium-177 that binds PSMA, is internalized, and emits beta particles to deliver localized radiation and induce tumor cell DNA damage.
nci_thesaurus_concept_id
C148145
nci_thesaurus_preferred_term
Lutetium Lu 177 Vipivotide Tetraxetan
nci_thesaurus_definition
A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.
drug_mesh_term
Pluvicto
drug_category
RADIOPEPTIDE CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
PSMA-targeted small-molecule/peptide radioligand (vipivotide tetraxetan) chelated to lutetium-177 that binds PSMA on prostate cancer cells, is internalized, and delivers beta-particle radiation, causing DNA double-strand breaks and tumor cell death, with potential short-range bystander effects; minor gamma emissions enable imaging.
drug_name
177Lu-PSMA-617
nct_id_drug_ref
NCT05766371